Although most patients with lymphoplasmacytic lymphoma/Waldenstro¨m macroglobulinemia (LPL/WM) have an indolent clinical course with a median survival of 60 months, 1 5-13% of them experience transformation into diffuse large B-cell lymphoma (DLBCL). [2] [3] [4] The prognosis after large-cell transformation is very poor, with a reported median survival of 2-5 months, 3, 4 and no effective therapeutic approach has been established. Here, we report a case of transformed DLBCL from LPL/WM successfully treated with sequential rituximab-based immunochemotherapy immediately followed by reduced-intensity conditioned allogeneic stem cell transplantation (RICT).
A 42-year-old Japanese woman was diagnosed with LPL/ WM on routine blood tests before hysterectomy. She had a serum monoclonal gammopathy of IgM kappa type without any clinical symptoms or any organ involvement on computed tomography scans. The disease was entirely confined to BM, with an infiltration of atypical lymphoplasmacytic cells exhibiting CD5À, CD10À, CD19 þ , CD20 þ , HLA-DRÀ, surface membrane IgM (sm-IgM) þ , sm-IgD þ , sm-IgGÀ, sm-kappa þ immunophenotype by flowcytometric analysis (FCM). She had been treated with chemotherapy including oral cyclophosphamide, melphalan or rituximab for 12 years because of high IgM levels ( Figure 1) .
When she was 54-year-old, she became refractory to those therapies, and was treated with two cycles of cladribine and mitoxantrone with a partial response. However, 2 months after completion of the chemotherapy, her lactate dehydrogenase (LDH) levels rose rapidly from 138 to 1461 IU/l, although her IgM levels remained stable (10 g/l). Although computed tomography scans did not show any abnormalities, BM examination demonstrated a hypercellular marrow with diffuse blastic cell infiltration. FCM studies of BM revealed two distinct tumor populations: the dominating larger cells expressed CD5À, CD10 þ , CD19 þ , CD20 þ , HLA-DR þ , sm-IgMÀ, smIgDÀ, sm-IgG þ , sm-kappa þ (CD10 þ /sm-IgMÀ cells, 48.3% of ANC) and minor smaller cells expressed CD5À,
.2% of ANC), which was identical to the immunophenotype of the pre-existing lymphoplasmacytic cells. G-banded cytogenetic analysis showed a normal karyotype. She was diagnosed with transformed DLBCL from LPL/WM and treated with three courses of EPOCH chemotherapy combined with rituximab (R-EPOCH), 5 resulting in a reduction of LDH (141 IU/l) and IgM (4.68 g/l). Computed tomography scans showed no abnormalities. However, serum immunoelectrophoresis showed residual IgM paraprotein and FCM studies demonstrated the residual CD10À/IgM þ tumor cells in BM (0.3% of ANC), indicating that she had achieved a complete response of the DLBCL and a partial response of the LPL/WM.
Because the presence of residual tumor cells in BM precluded the collection of an uncontaminated autologous graft, allogeneic SCT was considered the only potentially curative treatment option; however, the patient had neither an HLA-matched sibling donor nor a suitable unrelated donor. Therefore, after written informed consent had been obtained, she received a transplant of filgrastim-mobilized allogeneic peripheral blood stem cells (9.68 Â 10 8 mononuclear cells/kg, 6.36 Â 10 6 CD34 þ cells/kg) from her HLA partially mismatched daughter (one antigen mismatch in graft-versus-host direction, recipient A*2402/A*2602 B*5201/B*5201 DRB1*1502/DRB1*1502; donor A*2402/ A*2402 B*5201/B*4601 DRB1*1502/DRB1*0803), following a reduced-intensity preparative regimen consisting of fludarabine 25 mg/m 2 for 5 days, oral busulfan 4 mg/kg in divided dose daily for 2 days and total body irradiation 400 cGy (fractionated over 2 days). GVHD prophylaxis consisted of intravenous tacrolimus (0.03 mg/kg/day from day À3 to 28), short-course methotrexate (5 mg/m 2 on days 1, 3 and 6) and mycophenolate mofetil (30 mg/kg/day from day 7 to 27). No severe post transplant complications were experienced. On day 28, donor-cell engraftment with complete chimerism was confirmed. However, FCM studies of BM demonstrated a trace amount of residual CD10À/ smIgM þ tumor cells (0.16% of ANC) with persistence of the serum monoclonal IgM paraprotein. From day 28, tacrolimus was given orally and tapered gradually. There was no sign of acute GVHD. Chronic GVHD of the oral mucosa and liver developed 4 months after transplantation, but was well controlled with oral prednisolone. On day 308, tacrolimus was discontinued. On day 507, BM examination showed a normal marrow without residual tumor cells by FCM analysis. Her serum IgM levels gradually decreased (2.67 g/l on day 28 and 0.55 g/l at 31 months after SCT) suggesting a graft-versus-macroglobulinemia effect, although serum immunofixation electrophoresis still showed a trace amount of monoclonal IgM-kappa paraprotein. She is alive without DLBCL 33 months after the transformation.
Our report indicates that R-EPOCH as salvage therapy followed by RICT could be the treatment of choice for large cell transformation of LPL/WM which generally has a dismal prognosis. Lin et al. 4 reported that only one patient among 12 with DLBCL transformed from LPL/ WM achieved a complete remission and long-term survival (eight months) after aggressive chemotherapy with autologous SCT. Furthermore, Tsimberidou et al. 6 reported that patients with Richter's syndrome should be treated with chemotherapy and rituximab combination therapies and allo-SCT as post-remission therapy. In this report, conditioning regimens were mostly relatively nontoxic or reduced-intensity regimens. R-EPOCH has proven activity as salvage therapy, 7, 8 and was effective and well tolerated in heavily pretreated patients with relapsed/refractory DLBCL (including transformed type) and mantle-cell lymphoma. 5 For patients with advanced malignancy, unmanipulated allo-SCT from related donors other than HLA-matched siblings has been reported to be a reasonable alternative when a more suitable stem-cell source is not available. 9, 10 Taken together, we considered that intensive R-EPOCH chemotherapy alone could not control LPL/ WM in transformation and chose to perform RICT from a partially mismatched related donor as post-remission therapy.
Although a minor amount of serum IgM paraprotein was still detectable by immunofixation electrophoresis, her IgM levels gradually decreased after RICT and remained within the normal range without additional chemotherapy. Based on these observations, it is not unlikely that pretransplant R-EPOCH chemotherapy reduced the tumor burden sufficiently to confer a dual graft-versus-lymphoma effect against indolent LPL/WM and large cell lymphoma after RICT. In conclusion, to our knowledge, this is the first case of DLBCL transformed from LPL/WM successfully treated using sequential immunochemotherapy and RICT. R-EPOCH as salvage therapy followed by RICT would be feasible and a treatment of choice for DLBCL from LPL/WM. Further studies should be performed to clarify its efficacy as an alternative treatment option. 
